# Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)

> **NCT01098097** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 963 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** Peginterferon alpha
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01098097
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 963 (ACTUAL)
- **Last updated:** 2014-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098097, "Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01098097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*